ERBB2 and neoplasm: Taken together, our data suggest that the HER2/PD-L1 BsAb might enhance trastuzumab-mediated ADCC through IFN-γ-mediated upregulation of PD-L1 expression in both PD-L1+ and PD-L1− tumor cells.